Loading...
•
Sep 30, 2021
Eagle Q3 2021 Earnings Report
Reported a net loss of $0.43 per share and adjusted non-GAAP net income of $0.57 per share.
Key Takeaways
Eagle Pharmaceuticals reported a decrease in revenue to $39.9 million compared to $49.9 million in the same quarter last year. The company experienced a net loss of $5.6 million, or $0.43 per share, compared to a net income of $7.1 million, or $0.52 per share, in the third quarter of 2020. However, adjusted non-GAAP net income was $7.5 million, or $0.57 per share.
Q3 2021 net loss was $0.43 per basic and diluted share and adjusted non-GAAP net income was $0.57 per basic and $0.56 per diluted share
Expect to receive approval for Abbreviated New Drug Application (“ANDA”) for vasopressin; December 15, 2021 GDUFA date
Received favorable district court decision that Eagle’s proposed vasopressin product does not infringe any of the patents Par asserted against Eagle
Entered into worldwide licensing agreement for CAL02, a novel first-in-class antitoxin agent ready for Phase 2b/3 development for the treatment of severe bacterial pneumonia
Eagle
Eagle
Forward Guidance
We are preparing for two significant product launches, vasopressin and PEMFEXY™, expected within the next ninety days that we believe will meaningfully increase the revenue and profitability of Eagle. With the recent licensing of CAL02 and landiolol, our expectation going forward is that we will utilize our cash and possibly the balance sheet to further strengthen the pipeline and portfolio